Introduction
============

Parkinson's disease (PD) is currently considered the second most common neurodegenerative disorder, losing first place to Alzheimer's disease by a small margin.[@b1-cia-10-183],[@b2-cia-10-183] Functional disability caused by PD has a major impact on the lives of patients and their families. The progression of PD leads to an increasing inability to perform daily activities, loss of independence, and a decreased quality of life, and it generates socioeconomic and occupational impairments.[@b3-cia-10-183] Because of its complex and multifactorial etiology, which combines, in many cases, genetic, environmental, and lifestyle factors, PD is usually treated with pharmacological and surgical approaches, but these treatments are not always completely effective.[@b4-cia-10-183]

The motor impairment in PD patients caused by bradykinesia, rigidity, tremor, and postural instability accelerates the decline in functional capacity, especially when associated with decreased activity and with a sedentary lifestyle.[@b5-cia-10-183],[@b6-cia-10-183] Physical rehabilitation may be important for the maintenance and improvement of mobility, posture, and balance in PD patients.[@b7-cia-10-183] Different modalities of nonpharmacological treatment such as physiotherapy (P), walking, running, strength training (ST), functional exercises, and whole body vibration significantly reduced the risk of falls and improved motor performance,[@b8-cia-10-183],[@b9-cia-10-183] balance and gait,[@b10-cia-10-183] and executive functions.[@b11-cia-10-183] However, further discussion is required regarding the levels of physical exertion to which PD patients may be subjected.[@b12-cia-10-183] In this regard, P appears to have lower clinical effects[@b13-cia-10-183] when compared with aerobic training (AT)[@b14-cia-10-183] and ST.[@b15-cia-10-183] However, the possible differences among these interventions have not yet been investigated in a controlled study, to the best of our knowledge.

This trial aimed to compare the effects of P, AT, and ST on improvement of the symptoms of PD. The main hypothesis of this study was that an AT and/or an ST program would be superior to P in improving motor symptoms, based on the Unified Parkinson's Disease Rating Scale (UPDRS) subscale UPDRS-III. The secondary outcomes studied were functional capacity (Senior Fitness Test), balance, walking speed, and electroencephalographic activity (EEG) to examine possible central nervous system changes (activity of the cerebral cortex).

Materials and methods
=====================

Standard protocols and patient consent
--------------------------------------

A prospective longitudinal, randomized, controlled intervention study was conducted from September 2010 to September 2012. Patients with idiopathic PD diagnosed by neurologist experts in movement disorders were recruited from an outpatient rehabilitation department of the Federal University of Rio de Janeiro, Brasil. The inclusion criteria were age between 45 years and 80 years, a diagnosis of PD, and stage 1--3 on the Hoehn and Yahr scale.[@b16-cia-10-183] The exclusion criteria comprised any disease that hindered the application of an evaluation instrument, clinical comorbidities that make it impossible to use physical effort, individuals of New York Heart Association classes III and IV, significant physical limitations, and visual or hearing impairment. The patients were followed for 12 weeks. All subjects gave informed consent and the study was approved by the Ethics Committee of the Institute of Neurology Deolindo Couto (INDC) (protocol number 008-09-CEP).

Intervention
------------

We decided to compare the effects of three approaches, AT, ST, and P, all of which are widely used for the prevention and treatment of a number of diseases. We applied specific programs for each method to determine if and how they were able to increase the functional capacity and reduce the symptoms of PD. The programs were equivalent with respect to the time of intervention, duration, and weekly frequency. The patients were randomized by a blinded investigator and controlled for age, motor score in terms of UPDRS-III,[@b17-cia-10-183] and stage of the disease as defined by Hoehn and Yahr scale.[@b18-cia-10-183] They participated in their respective interventions twice a week for 12 weeks. All patients performed exercise sessions supervised by trained coaches. Patients were advised not to perform additional exercises.

Aerobic training
----------------

The AT program consisted of 30 minutes of treadmill walking (Jog 500, Technogym^®^; Italy) preceded by 5 minutes of warming and 5 minutes of postexercise recovery. The training intensity corresponded to 60% of the maximum oxygen consumption (VO~2max~) or 70% of the maximum heart rate (HR~max~) predicted by age and determined by the formula HR~max~=208−(0.7× age).[@b19-cia-10-183] The speed and treadmill inclination were changed so that the patients maintained the same intensity of training during the 12-week intervention. The VO~2~ during training was obtained by the walking equation described by the American College of Sports Medicine, VO~2~=\[0.1 (velocity) +1.8 (velocity) (inclination/100) +3.5\], where the velocity is given in m/min.[@b20-cia-10-183]

Strength training
-----------------

The ST program consisted of exercises for large muscle groups using equipment for leg extensions, leg curls, leg presses, chest presses, and low row. All equipment was from the line Selection (Technogym^®^; Italy). The daily training volume was composed of two series of eight to 12 maximum repetitions for each exercise with rest intervals of 1 minute and 30 seconds between the sets. The initial training intensity was set between 70% and 80% of the value obtained in the one repetition maximum test, and the training load was constantly adjusted to maintain the maximum repetitions. The patients were instructed to perform a warm-up on each machine with minimum load before starting the training and to perform a stretching session at the end of the training.

Physiotherapy
-------------

The P group program consisted of calisthenics for the upper and lower limbs, stretching, and gait training in a 12 m hallway, led by a physiotherapist. The sessions lasted approximately 30--40 minutes and no type of overload was used in the proposed activities.

Study procedures
----------------

All patients were evaluated for the effect of dopaminergic medication during the training period. The motor symptoms were assessed using UPDRS-III by a single evaluator certified by the Movement Disorder Society (AC). The global cognitive status was assessed using the Mini-Mental State Examination.[@b21-cia-10-183]

To assess functional capacity, the following tests (from the Senior Fitness Test) were used:[@b22-cia-10-183] the Chair Stand Test (CST), Arm Curl Test (ACT), 2-Minute Step Test (2-MST), Chair Sit and Reach Test (CSRT), Back Scratch Test (BST), and 8-Foot Up and Go Test (8-FT). In addition, we used the 10-Meter Walk Test (10-MWT)[@b23-cia-10-183] and Berg Balance Scale (Berg).[@b24-cia-10-183] All these tests have good reliability and validity values.[@b22-cia-10-183]

The EEG mean frequency (MF) was recorded and analyzed following the protocol used in a previous study from our laboratory.[@b25-cia-10-183] The MF may also be modified by pharmacological and environmental interventions. Physical exercise increases the MF throughout the cortex;[@b26-cia-10-183] however, there is no evidence in relation to patients with PD.

The patients returned to the laboratory after 3 months for follow-up. The whole process of the baseline assessment was repeated by the same examiner. Current medications and any adverse effects were recorded at each visit.

Statistical analysis
--------------------

The mean and standard deviation were computed for parametric variables and the *χ* test was used for categorical variables for descriptive analysis. To test for the normality and homoscedasticity of the deltas (post and pre), the Shapiro-Wilk test and Levene's tests were applied, respectively.

To compare the deltas (post and pre) between groups (AT, ST, and P), one-way analysis of variance (ANOVA) was performed for all physical tests (UPDRS, 8-FT, CST, 2-MST, ACT, BST, CSRT, Berg, 10-MWT). Significant differences in ANOVA were analyzed by the Bonferroni post hoc test.

Furthermore, we decided to use analysis of effect size (ES) in addition to traditional statistics, comparing the results obtained by all interventions to assess the clinical relevance of our findings. The ES analysis was performed using the formula proposed by Cohen.[@b27-cia-10-183] The values of the ES were classified as trivial (0.20≤ES\<0.50), moderate (0.50≤ES\<0.80), and large (ES≥0.80).

For analyzing the values of EEG MF, the electrodes were divided into six areas (frontal pole, frontal, central, temporal, parietal, and occipital).[@b28-cia-10-183] These areas are composed of electrodes Fp1, Fp2, and Fz (frontal pole); F4, F3, F7, and F8 (frontal); C3 and C4 (central); T3, T4, T5, and T6 (temporal); P3 and P4 (parietal); and O1 and O2 (occipital). The statistical model employed was a three-way ANOVA to obtain comparisons among moment (pre and post), the group (ST, AT, and P), and the area (frontal pole, frontal, central, parietal, temporal, and occipital). The statistical package SPSS^®^ version 20.0 for Windows (IBM Corporation, Armonk, NY, USA) was used for all analyses, and the accepted significance level for this study was *P*≤0.05.

Results
=======

All variables investigated showed normality and homoscedasticity and therefore parametric analyzes were performed. Twenty-two patients were randomly assigned to the three groups ([Figure 1](#f1-cia-10-183){ref-type="fig"}). The only difference among the groups was found in the use of dopamine agonists, most used by the P group ([Table 1](#t1-cia-10-183){ref-type="table"}).

Symptoms of disease
-------------------

Regarding the stages of PD (Hoehn and Yahr scale), 4.5% of the patients were in stage I, 54.5% in stage II, and 41% in stage III. There was no significant difference between the deltas of the three groups for the subscales of the UPDRS ([Table 2](#t2-cia-10-183){ref-type="table"}).

The ST group showed a large ES in UPDRS-I (ES=0.93) and UPDRS-III (ES=1.25), presenting improved behavioral and motor symptoms. The AT group presented a large ES in UPDRS-II (ES=1.12) and UPDRS-III (ES=1.34). There was no effect in UPDRS-I (ES=0.00) and worsening of symptoms in UPDRS-IV (ES=−1.23). The P group presented a trivial ES in UPDRS-III (ES=0.07) and UPDRS-I (ES=0.21) and worsening of symptoms in UPDRS-II (ES=−0.13) and UPDRS-IV (ES=−0.51) ([Figure 2](#f2-cia-10-183){ref-type="fig"}).

Functional capacity
-------------------

In comparing the deltas of the functional capacity tests there was a significant difference among the groups (*F*=5.65, *P*=0.01) in their aerobic capacity assessed by the 2-MST. The Bonferroni post hoc test revealed that the ST and AT groups showed significant improvement after training, which was absent in the P group. There were no statistically significant differences among the groups for the analyses of the deltas of the other functional capacity tests ([Table 2](#t2-cia-10-183){ref-type="table"}).

In the analysis of ES, the ST group had a large ES in the 8-FT (ES=−1.18) and CST (ES=1.81); a moderate ES in the ACT (ES=0.74), 2-MST (ES=0.72), and 10-MWT (ES=0.78); and a trivial ES in the BST (ES=0.38), CSRT (ES=0.28), and Berg (ES=0.44). The AT group showed a large ES in the 8-FT (ES=1.08), ACT (ES=1.16), CST (ES=0.86), and 10-MWT (ES=1.20); a moderate ES in the BST (ES=0.79) and 2-MST (ES=0.69); and a trivial ES in Berg (ES=0.38). The P group showed a large ES in the 8-FT (ES=1.35), a moderate ES in the CST (ES=0.57), a trivial ES in the BST (ES=0.41) and 10-MWT (ES=0.34), and worsening of symptoms in the 2-MST (ES=−0.73) ([Table 2](#t2-cia-10-183){ref-type="table"}).

EEG MF
------

The results of the EEG MF analysis primarily demonstrated the effect of the interventions on the groups (*F*=11.50, *P*=0.00), without giving significance to area (*F*=1.98, *P*=0.97), moment (*F*=0.01, *P*=0.89), and interactions between moment × group (*F*=2.36, *P*=0.09), moment × area (*F*=0.27, *P*=0.93), group × area (*F*=0.21, *P*=0.99), and moment × group × area (*F*=0.23, *P*=0.93). The AT and ST groups showed higher MF compared with the P group, which is related to increased cortical activation. [Figure 3](#f3-cia-10-183){ref-type="fig"} illustrates the cortical activity of the groups using cortical maps with the delta values. The yellow and orange colors represent increased cortical activity in the anterior and posterior areas of the cortex. The violet, black, and green colors represent decreased cortical activity in the same areas.

Discussion
==========

This study aimed to compare the effects of ST, AT, and P as supplementary treatments for the motor symptoms of PD in a randomized controlled design. Our results showed that after 3 months of intervention, the improvement in PD symptoms was similar between the groups that performed AT and ST, and this improvement was greater than that of the group that was on P sessions. To the best of our knowledge, this is the first study to compare two types of exercise (AT and ST) with a group that was submitted to P as a control group. We found that the effects in the exercise groups are not only due to physical activity but possibly associated with physiological changes in response to training with a controlled overload and progression of intensity. This inference is further strengthened by the observation that the largest ES was found in the groups that had undergone AT and ST.

The groups of patients that underwent AT and ST showed significant clinical improvements in the motor symptoms of PD, as well as in functional capacity, indicating that prescribing exercise with controlled intensity, duration, and frequency may improve the physical health of patients with PD. There was a 27.5% and 35% improvement in motor symptoms (UPDRS-III) for the ST and AT groups, respectively, in contrast to a 2.9% improvement for the P group. These results demonstrate that pharmacological treatment associated with physical exercise (AT and/or ST) may promote better results for symptoms such as rigidity and bradykinesia than just abiding to the conventional P usually prescribed to PD patients. Our hypothesis was also recently confirmed by Tambosco et al[@b12-cia-10-183] who illustrated that the inclusion of AT and ST was effective in rehabilitation programs for PD patients. Our results also corroborate the findings of Dibble et al[@b29-cia-10-183] Ridgel et al[@b30-cia-10-183] and Alberts et al[@b14-cia-10-183] who showed that AT and ST associated with pharmacological treatment are capable of promoting positive responses in the cardinal symptoms of PD. In a preliminary study, Dibble et al[@b29-cia-10-183] submitted ten PD patients for 12 weeks of an ST program with high intensity (80% HR~max~), lasting 45--60 minutes, three times a week. The patients showed an improvement in bradykinesia assessed by speed walking tests (ES=0.68) and agility (ES=0.59), compared with an active control group (ES=0.07).[@b29-cia-10-183] Ridgel et al[@b30-cia-10-183] and Alberts et al[@b14-cia-10-183] observed a 35% improvement in motor symptoms after submitting PD patients for 3 weeks of forced training on a cycloergometer.[@b14-cia-10-183],[@b30-cia-10-183] In contrast to the conclusion of Alberts et al[@b14-cia-10-183] that forced aerobic exercise would be more effective than voluntary exercise for improving motor symptoms of PD, our results showed that there was a 35% improvement in motor symptoms on UPDRS-III in the volunteer subjects who walked on a treadmill with due control of workout intensity.

In relation to functional capacity, ST and AT significantly improved the patients' aerobic capacity, measured by the 2-MST. Moreover, by studying the ES, we found that the ST and AT groups improved in agility, strength of the upper and lower limbs, lower limb endurance, walking speed, and dynamic balance. The AT group also showed an improvement in the flexibility of the upper limbs. The group submitted to P also improved in agility and lower limb strength. However, the flexibility and endurance of the lower limbs worsened after the intervention period. These results demonstrate the effect of exercise on improving variables such as strength, flexibility, and especially aerobic endurance.[@b12-cia-10-183] There was no difference between exercise and P in improving variables such as agility and balance.

Concerning the EEG, the ST and AT groups showed an increase in MF compared with the P group. As far as we know, our study is also the first to use EEG results to evaluate the effect of exercise and P in the treatment of PD. In PD patients, diffuse slowing of EEG was present according to progression of disease, and this phenomenon implies an impairment of neural activity, with implications on cognition, executive function, and motor function.[@b31-cia-10-183],[@b32-cia-10-183] The MF is a measure comprising all frequency bands of the EEG (delta, theta, alpha, beta, and gamma) and is positively correlated with cerebral blood flow and glucose metabolism.[@b28-cia-10-183] Herz et al[@b33-cia-10-183] observed that dopaminergic treatment appears to increase the beta and gamma frequency bands of the EEG in prefrontal and premotor areas. Our results suggest that exercise positively influences cortical activity in PD patients. During the execution of physical exercise, more cortical areas are activated, and the main hypothesis of this phenomenon is the increase in cerebral blood flow during exercise.[@b28-cia-10-183] Studies on other diseases such as major depression demonstrated that AT promotes a change in asymmetry[@b34-cia-10-183] and an increase in the MF of the EEG.[@b34-cia-10-183],[@b35-cia-10-183] Therefore, our results corroborate the evidence on the positive effect of exercise on the brain and on mental health. Likewise, Alberts et al[@b14-cia-10-183] demonstrated increased activity in the cortical and subcortical areas through functional magnetic resonance imaging immediately after AT.

Studies performed in animal models suggest that the physiological adaptations promoted by exercise with intensity seem to promote structural changes in the brain, mediated by increased expression of trophic factors such as brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, vascular endothelial growth factor, and insulin-like growth factor 1, positively influencing brain functions (motor, cognitive, and behavioral).[@b14-cia-10-183],[@b36-cia-10-183],[@b37-cia-10-183] Further translational studies in humans are warranted to find out whether this is also the fact in PD patients.

The present study has some limitations that should be considered. The use of a small number of subjects in each group may be associated with type II error. This limited sample size has to be taken into account when interpreting to what extent the results can be generalized, particularly given the well-known heterogeneity among PD patients. Moreover, patients with PD present several comorbidities (eg, cardiovascular and mood disorders) that were not investigated in the present study, and it is important to observe the effects of exercise in these patients. Due to this fact, we did not limit our analysis to the test of statistical significance by rejecting the null hypothesis. Instead, we looked into the magnitude of the effect, which demonstrated the clinical application of our findings. For future research, we suggest applying and controlling variables such as other training intensities, combining different approaches (combined AT and ST), and analyzing hormones and trophic factors of the patients.

Conclusion
==========

Aerobic and strength training, controlled by parameters of intensity, duration, and frequency, showed a greater improvement than conventional physical therapy in symptoms and cortical activity of PD patients, confirming the need for a systematic program of training with controlled intensity. Therefore, both strength and aerobic training associated with pharmacological treatment may contribute to improving response to the treatment of PD and must be prescribed to improve the physical and mental health of patients.
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![Flow diagram for identification of eligible patients.\
**Abbreviations:** AT, aerobic training; P, physiotherapy; PD, Parkinson's disease; ST, strength training.](cia-10-183Fig1){#f1-cia-10-183}

![Effect size (ES) of symptoms of Parkinson's disease.\
**Abbreviations:** CI, confidence interval; L, large; M, moderated; S, small; UPDRS, Unified Parkinson's Disease Rating Scale; UPDRS-I, behavioral; UPDRS-II, activities of daily living; UPDRS-III, motor examination; UPDRS-IV, pharmacological complications.](cia-10-183Fig2){#f2-cia-10-183}

![Spectral analysis of mean frequency by delta (post and pre) of aerobic training (AT), strength training (ST), and physiotherapy (P) groups.^a^\
**Note:** ^a^The yellow and orange colors represent increased cortical activation after intervention.\
**Abbreviations:** AA, anterior area; PA, posterior area.](cia-10-183Fig3){#f3-cia-10-183}

###### 

Descriptive analysis of the three groups (physiotherapy \[P\], aerobic training \[AT\], and strength training \[ST\]) at baseline

  Variables                 AT (n=5) mean (SD)   ST (n=8) mean (SD)   P (n=9) mean (SD)   *P*-value
  ------------------------- -------------------- -------------------- ------------------- -------------------------------------------------
  Education (years)         6.8 (3.2)            9.8 (4.8)            10.7 (4.5)          0.312
  Age (years)               64.8 (11.9)          64.1 (9.9)           62.1 (11.7)         0.893
  Sex (% men)               80.0                 71.4                 55.6                0.614
  MMSE (score)              24.6 (4.0)           25.8 (3.2)           26.5 (2.9)          0.585
  Weight (kg)               64.2 (13.5)          69.2 (16.9)          69.0 (16.1)         0.836
  Height (cm)               165.4 (11.6)         167.5 (3.4)          165.5 (9.3)         0.877
  Time of disease (years)   6.6 (1.5)            6.0 (2.6)            4.3 (2.8)           0.238
  Stage of disease (H&Y)    2.6 (0.5)            2.1 (0.6)            2.3 (0.5)           0.429
  UPDRS-I (score)           3.0 (2.4)            3.4 (1.9)            3.1 (2.3)           0.931
  UPDRS-II (score)          14.6 (5.1)           13.0 (5.3)           10.0 (4.5)          0.232
  UPDRS-III (score)         31.0 (10.0)          40.4 (9.7)           34.9 (8.6)          0.233
  UPDRS-IV (score)          2.8 (2.0)            4.2 (2.8)            4.4 (3.0)           0.544
  Levodopa (%)              18.2                 36.4                 31.8                0.385
  Dopamine agonist (%)      18.2                 27.3                 9.1                 0.040[a](#tfn2-cia-10-183){ref-type="table-fn"}
  Amantadine (%)            9.1                  18.2                 4.5                 0.126
  COMT inhibitor (%)        0                    0                    4.5                 0.487
  Others (%)                13.6                 22.7                 13.6                0.448

**Notes:** Level of statistical significance *P*≤0.05.

Significant difference between groups.

**Abbreviations:** COMT, catechol O-methyltransferase; H&Y, Hoehn and Yahr scale; MMSE, Mini-Mental State Examination; SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating scale; UPDRS-I, behavioral; UPDRS-II, activities of daily living; UPDRS-III, motor examination; UPDRS-IV, pharmacological complications.

###### 

Comparison of symptoms of Parkinson's disease and functional capacity (pre and post) of aerobic training, strength training, and physiotherapy

                        Strength training (n=8)   Aerobic training (n=5)   Physiotherapy (n=9)   *F*           *P*-value                                                          
  --------------------- ------------------------- ------------------------ --------------------- ------------- ------------ ------- -------------- -------------- ------- ------- -------------------------------------------------
  UPDRS-I (score)       3.8(2.1)                  2.1 (1.5)                −0.93                 3.0 (2.4)     3.0 (2.3)    0.00    3.1 (2.4)      2.6 (2.4)      −0.21   0.948   0.405
  UPDRS-II (score)      14.3 (6.3)                1 1.7 (5.0)              −0.46                 14.6(6.1)     8.2 (5.3)    −1.12   10.0(4.5)      1 1.0(10.1)    0.13    1.236   0.313
  UPDRS-III (score)     42.1 (10.2)               30.5 (8.3)               −1.25                 31.0(10.0)    20.2 (5.5)   −1.34   34.9 (8.6)     33.9(17.0)     −0.07   1.332   0.287
  UPDRS-IV (score)      4.6 (2.8)                 3.4 (2.4)                −0.46                 2.8 (2.0)     5.8 (2.8)    1.23    4.4 (3.0)      7.0 (6.6)      0.51    1.205   0.322
  8-FT (s)              9.5 (2.8)                 7.0(1.1)                 −1.18                 10.1 (3.4)    7.0(1.4)     −1.08   9.6 (2.2)      7.2(1.0)       −1.35   0.153   0.859
  BST (cm)              22.4(10.5)                17.7(13.8)               −0.38                 23.6(14.8)    10.8(17.4)   −0.79   23.3 (1 1.3)   18.0(14.4)     −0.41   1.149   0.338
  CSRT (cm)             8.6 (9.2)                 6.5 (5.5)                −0.28                 8 (7.6)       8.6(12.0)    −0.06   10.2(10.2)     1 I.I (11.5)   0.08    0.313   0.735
  ACT (repetitions)     14.3 (4.9)                18.0(5.1)                0.74                  1 1.8 (3.9)   16.4(4.0)    1.16    14.9 (4.7)     15.2(3.3)      0.07    1.400   0.271
  CST (repetitions)     10.2(3.1)                 15.0(2.1)                1.81                  10.4(4.5)     13.4 (2.0)   0.86    10.7(3.2)      12.3 (2.3)     0.57    1.184   0.328
  2-MST (repetitions)   46.7 (20.2)               61.1 (20.0)              0.72                  50.6 (36.0)   68.6 (8.4)   0.69    57.9 (20.7)    42.7 (20.8)    −0.73   5.657   0.012[a](#tfn5-cia-10-183){ref-type="table-fn"}
  10-MWT(s)             8.0(3.1)                  6.2(1.0)                 −0.78                 9.0 (2.9)     6.5 (0.5)    −1.20   7.2(1.8)       6.7(1.0)       −0.34   1.122   0.346
  Berg (score)          50.3 (4.9)                52.5(5.1)                0.44                  52.6 (4.7)    54.0 (2.4)   0.38    52.5 (2.3)     52.5 (3.6)     0.00    0.333   0.721

**Notes:** Level of statistical significance P≤0.05.

Significant difference between groups.

**Abbreviations:** 2-MST, 2-Minute Step Test; 8-FT, 8-Foot Up and Go Test; 10-MWT, 10-Meter Walk Test; ACT, Arm Curl Test; Berg, Berg Balance Scale; BST, Back Scratch Test; CSRT, Chair Sit and Reach Test; CST, Chair Stand Test; ES, effect size; SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating Scale; UPDRS-I, behavioral; UPDRS-II, activities of daily living; UPDRS-III, motor examination; UPDRS-IV, pharmacological complications.
